TITLE

Two diabetes trials leave Benicar at a crossroads

PUB. DATE
June 2010
SOURCE
Reactions Weekly;6/19/2010, Issue 1306, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article deals with the safety review of the antihypertensive medication, olmesartan, being conducted by the U.S. Food and Drug Administration in June 2010.
ACCESSION #
51608561

 

Related Articles

  • FDA approves Exforge HCT for treatment of hypertension.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p59 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to the antihypertensive drug Exforge HCT for patients with moderate-to-severe hypertension.

  • FDA Approvals In December.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p6 

    A chart is presented that lists the drugs approved by the U.S. Food and Drug Administration (FDA) in December 2010, Cubicin from Cubist Pharmaceuticals Inc. and Fortesta from Endo Pharmaceuticals Inc.

  • Recombinant human GH safety review ongoing.  // Endocrine Today;Jan2011, Vol. 9 Issue 1, p32 

    This article reports on the move of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a review to examine the safety of somatropin containing medications.

  • Bleeding Risk Evaluated.  // Monthly Prescribing Reference;Dec2012, Vol. 28 Issue 12, pA16 

    The article reports that the U.S. Food and Drug Administration (FDA) has conducted and evaluation of the risks of serious bleeding related to dabigatran and warfarin.

  • Dear editor,. Schafranski, Marcelo Derbli; Grossa, Ponta // Brazilian Journal of Cardiovascular Surgery;jul-sep2013, Vol. 28 Issue 3, p413 

    A letter to the editor is presented in response to the phase 0 clinical studies which follows the guidelines of the Food and Drug Administration (FDA) established in 2006 to guide the Exploratory Investigational New Drug Studies and safety and tolerability of Phase I clinical studies.

  • Alert for Invirase & Norvir.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA19 

    The article reports on the plans of the U.S. Food and Drugs (FDA) to review the clinical trial data about a potentially serious effect on the heart associated with the use of Invirase, a saquinavir drug from Roche, in combination with Norvir, a ritonavir drug from Abbott.

  • Amylin's diabetes shock. Subbaraman, Nidhi // Nature Biotechnology;Dec2010, Vol. 28 Issue 12, p1224 

    The article reports on the call by the U.S. Food and Drug Administration for further test on Bydureon, a once-weekly drug for type 2 diabetes from Amylin.

  • FDA Restricts Enrollment in GSK's Avandia Study.  // Bioworld Week;7/26/2010, Vol. 18 Issue 30, p4 

    The article reports that the Food and Drug Administration (FDA) has restricted patients from enrolling in the type II diabetes drug Avandia study of GlaxosmithKline in the U.S.

  • As I See It. Kamp, John // Medical Marketing & Media;Apr2010, Vol. 45 Issue 4, p32 

    The article discusses the implications of submitting the promotion materials to the Division of Drug Marketing, Advertising and Communications (DDMAC) Food and Drug Administration (FDA) for review in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics